SCILEX HOLDING COMPANY (“Scilex”) , a majority-owned subsidiary of Sorrento, is dedicated to the development and commercialization of pain management products. The company’s lead product ZTlido® (lidocaine topical system 1.8%), is a branded prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain.

Scilex’s SP-102 (10 mg dexamethasone sodium phosphate gel), or SEMDEXA™, for the treatment of Lumbar Radicular Pain is in the process of completing a Phase III clinical trial. The company expects SP-102 to be the first FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica, with the potential to replace 10 to 11 million off-label epidural steroid injections administered each year in the US.